Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

postmenopausal osteoporosis

- PMLiVE

UCB boosts gene therapy offering with a pair of new deals

Company will collaborate with Lacerta Therapeutics and acquire Handl Therapeutics

- PMLiVE

AZ, Amgen’s investigational asthma drug comes good in phase 3

Tezepelumab evaluated in late-stage trial of severe asthma patients

- PMLiVE

Amgen, Cytokinetics’ heart failure drug disappoints in phase 3

Drug hit primary endpoint but missed secondary endpoint of reduction in cardiovascular death

- PMLiVE

AbbVie, Amgen and Takeda team up for joint COVID-19 trial

Collaborative trial will evaluate three anti-inflammatory drugs

- PMLiVE

Roche pays $120m upfront for UCB’s anti-tau Alzheimer’s drug

Milestone payments could reach up to $2bn

- PMLiVE

Trial of Amgen, Servier’s heart failure drug clears interim check

Drug could become a $2bn product if approved

- PMLiVE

UCB/Amgen’s Evenity finally cleared for osteoporosis in Europe

First new drug for the disease in the EU since 2010

- PMLiVE

UCB’s bimekizumab beats AbbVie’s Humira in phase 3 trial

Met key primary and secondary trial endpoints

- PMLiVE

Roche’s Soliris rival satralizumab scores in phase 3 study

Therapy has been filed in US and Europe with decisions expected in 2020

- PMLiVE

Amgen raises forecasts after closing $13.4bn Otezla deal

Scope to build product further with ongoing trials in additional indications

China flag thumb

Amgen buys BeiGene stake for $2.7bn to aid push into China

China's oncology market forecast to nearly double in size by 2026

- PMLiVE

Amgen exits neuroscience R&D to focus on growth areas

Move has resulted in loss of around 180 jobs

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links